Biocon Pharma Ltd has secured approval from China's National Medical Products Administration (NMPA) for its Tacrolimus capsules available in 0.5mg, 1mg, and 5mg dosages. Tacrolimus, an immunosuppressive medication, is utilized to inhibit organ...
India now represents 60% of worldwide vaccine production and hosts the second-highest number of USFDA-approved manufacturing facilities outside the United States. As investment prospects expand in areas like Bio-Pharma, Bio-Agri, Bio-Industrial...
According to recent data, 54% of advanced biotech laboratories have identified gene-editing research as their main growth engine this year, highlighting the increasing importance of this sector. The worldwide gene therapy market had a valuation of...
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated...
In terms of government support, the production linked incentive (PLI) initiative and the creation of greenfield projects have been vital in enhancing India's local pharmaceutical sector. Ruchi Sogarwal, head of corporate affairs at Takeda India...
Indian pharmaceutical firms have achieved significant progress in complying with rigorous US Food and Drug Administration (USFDA) standards in 2024, with evidence indicating a reduction in adverse classification results from inspections involving...
The Andhra Pradesh MedTech Zone (AMTZ), established as India's first dedicated medical technology park in Visakhapatnam, has emerged as a vital hub in the global medical technology ecosystem, according to its Managing Director and founder CEO, Jit...
Chhattisgarh is positioning itself as a new pharmaceutical centre in central India, with the Naya Raipur Atal Nagar Development Authority allocating 141.84 acres in Sector-22 to foster research, development, and international investment in pharma...
Mankind Pharma Limited and Innovent Biologics have announced partnership to exclusively license and commercialize sintilimab, an advanced PD-1 immunotherapy, in the Indian market. This strategic collaboration aims to address the critical challenge...
India’s medical devices exports rose at a CAGR of 14% from FY20 to reach reach $3.8 billion in FY24. However, the country continues to remain a net importer of medical devices, bringing in 80-85% of its domestic requirements from abroad...
, CDSCO.jpg)
